Exenatide Use in the Management of Type 2 Diabetes Mellitus
Exenatide is a GLP-1 (glucagon-like peptide-1) agonist that has been approved in the UK for use in the management of Type 2 Diabetes Mellitus (T2DM) since 2006. It acts by increasing glucose-induced insulin release and by reducing glucagon secretion postprandially. It therefore increases insulin sec...
Saved in:
Main Authors: | Angelos Kyriacou (Author), Abu Baker Ahmed (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2010-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
by: Inaishi J, et al.
Published: (2022) -
Effects of Exenatide on Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes
by: Zhang Y, et al.
Published: (2021) -
A review of exenatide as adjunctive therapy in patients with type 2 diabetes
by: Gisela I Robles, et al.
Published: (2009) -
The effect of exenatide on fasting bile acids in newly diagnosed type 2 diabetes mellitus patients, a pilot study
by: Boyu Li, et al.
Published: (2020) -
Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide
by: Jonathan Pinkney, et al.
Published: (2010)